These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8637494)

  • 21. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate cancer: A challenge for screening.
    Donnell RF
    Surg Oncol Clin N Am; 1999 Oct; 8(4):693-702, vii. PubMed ID: 10452935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 27. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract]   [Full Text] [Related]  

  • 28. [Screening for prostate cancer--what does the evidence show?].
    Borre M; Iversen P
    Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 30. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 31. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 32. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Thompson IM; Tangen CM; Kristal AR
    J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671
    [No Abstract]   [Full Text] [Related]  

  • 35. [Screening in prostate carcinoma].
    Wirth MP; Spiegel T; Froschermaier SE; Manseck A
    Z Arztl Fortbild Qualitatssich; 1998 Jun; 92(5):304-9. PubMed ID: 9702818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is screening for prostate cancer the current gold standard?--"yes".
    Lange PH
    Eur J Cancer; 1997 Mar; 33(3):354-6. PubMed ID: 9155516
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ; Zappa M; Määttänen L; Ciatto S
    Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].
    Suzuki H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):16-20. PubMed ID: 12557699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate specific antigen screening.
    Block KI
    Integr Cancer Ther; 2009 Jun; 8(2):111-2. PubMed ID: 19679618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.